Stem cell firm opening raises questions
By Associated Press,
Associated Press
| 05. 01. 2008
A California-based stem cell research company will get $589,000 in state grants to open a New Jersey facility and create 12 new jobs, a plan questioned by those worried about the governor's proposed budget cuts.
"It does seem questionable to be writing checks to companies that are going to hire 12 people when you're cutting higher education and can't pay for transportation," said Jon Shure, president of the liberal-leaning New Jersey Policy Perspective that has criticized taxpayer-funded business incentives and tax breaks.
Democratic Gov. Jon S. Corzine, who joined officials from StemCyte and Rutgers University on Thursday to announce StemCyte's plan to open a facility in Ewing, defended the incentives.
"The addition of StemCyte to our portfolio of companies represents an important economic investment that brings with it the promise of discovery and cures for some of our most devastating diseases and injuries," Corzine said as he toured a Rutgers stem cell lab. "I am proud to welcome StemCyte to the Garden State."
The Ewing facility will house executive management and therapeutics team members, and serve as an East Coast...
Related Articles
By Katherine Long, Ben Foldy, and Lingling Wei, The Wall Street Journal | 12.13.2025
Inside a closed Los Angeles courtroom, something wasn’t right.
Clerks working for family court Judge Amy Pellman were reviewing routine surrogacy petitions when they spotted an unusual pattern: the same name, again and again.
A Chinese billionaire was seeking parental...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Sarah Kliff, The New York Times | 12.10.2025
Micah Nerio had known since his early 30s that he wanted to be a father, even if he did not have a partner. He spent a decade saving up to pursue surrogacy, an expensive process where he would create embryos...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
